[go: up one dir, main page]

WO2010118367A3 - Pyrimidines antivirales - Google Patents

Pyrimidines antivirales Download PDF

Info

Publication number
WO2010118367A3
WO2010118367A3 PCT/US2010/030598 US2010030598W WO2010118367A3 WO 2010118367 A3 WO2010118367 A3 WO 2010118367A3 US 2010030598 W US2010030598 W US 2010030598W WO 2010118367 A3 WO2010118367 A3 WO 2010118367A3
Authority
WO
WIPO (PCT)
Prior art keywords
compounds
infection
pyrimidines
pyrazolopyrimtdines
virus
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US2010/030598
Other languages
English (en)
Other versions
WO2010118367A2 (fr
Inventor
Amy Qi Han
Eric Wang
Carla Gauss
Walter Xie
Glen Coburn
Jean-Marc Demuys
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Progenics Pharmaceuticals Inc
Original Assignee
Progenics Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Progenics Pharmaceuticals Inc filed Critical Progenics Pharmaceuticals Inc
Publication of WO2010118367A2 publication Critical patent/WO2010118367A2/fr
Publication of WO2010118367A3 publication Critical patent/WO2010118367A3/fr
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/32—One oxygen, sulfur or nitrogen atom
    • C07D239/42—One nitrogen atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
    • C07D239/47—One nitrogen atom and one oxygen or sulfur atom, e.g. cytosine
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
    • C07D239/48—Two nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
    • C07D239/52—Two oxygen atoms
    • C07D239/54—Two oxygen atoms as doubly bound oxygen atoms or as unsubstituted hydroxy radicals
    • C07D239/545—Two oxygen atoms as doubly bound oxygen atoms or as unsubstituted hydroxy radicals with other hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/553—Two oxygen atoms as doubly bound oxygen atoms or as unsubstituted hydroxy radicals with other hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms with halogen atoms or nitro radicals directly attached to ring carbon atoms, e.g. fluorouracil
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Virology (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Communicable Diseases (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

La présente invention concerne de nouveaux composés comprenant des pyrimidines, des pyrazolopyrimidines, et des imidazolopyrimidines substituées, leurs synthèses, et des compositions les comprenant, y compris des compositions pharmaceutiques, comprenant les nouvelles pyrimidines, pyrazolopyrimidines, imidazolpyrimidines et des composés analogues. De tels composés fonctionnent en inhibant l'entrée des virus de la famille des Flaviviridae, y compris le virus de l'hépatite C (VHC), à l'intérieur des cellules qui sont susceptibles d'être infectées par les virus. Ces composés sont utiles dans le traitement, la thérapie et/ou la prophylaxie de maladies virales et d'infections, y compris l'infection par le VHC.
PCT/US2010/030598 2009-04-10 2010-04-09 Pyrimidines antivirales Ceased WO2010118367A2 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US16832309P 2009-04-10 2009-04-10
US61/168,323 2009-04-10

Publications (2)

Publication Number Publication Date
WO2010118367A2 WO2010118367A2 (fr) 2010-10-14
WO2010118367A3 true WO2010118367A3 (fr) 2011-03-10

Family

ID=42936895

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2010/030598 Ceased WO2010118367A2 (fr) 2009-04-10 2010-04-09 Pyrimidines antivirales

Country Status (1)

Country Link
WO (1) WO2010118367A2 (fr)

Cited By (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8476282B2 (en) 2008-11-03 2013-07-02 Intellikine Llc Benzoxazole kinase inhibitors and methods of use
US8637542B2 (en) 2008-03-14 2014-01-28 Intellikine, Inc. Kinase inhibitors and methods of use
US8993580B2 (en) 2008-03-14 2015-03-31 Intellikine Llc Benzothiazole kinase inhibitors and methods of use
US9096611B2 (en) 2008-07-08 2015-08-04 Intellikine Llc Kinase inhibitors and methods of use
US9295673B2 (en) 2011-02-23 2016-03-29 Intellikine Llc Combination of mTOR inhibitors and P13-kinase inhibitors, and uses thereof
US9359349B2 (en) 2007-10-04 2016-06-07 Intellikine Llc Substituted quinazolines as kinase inhibitors
US9718825B2 (en) 2013-03-13 2017-08-01 Sanofi N-(4-(azaindazol-6-yl)-phenyl)-sulfonamides and their use as pharmaceuticals
US11730736B2 (en) 2017-11-06 2023-08-22 Rapt Therapeutics, Inc. Anticancer agents

Families Citing this family (84)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW201602113A (zh) 2009-06-29 2016-01-16 英塞特公司 作為ｐｉ３ｋ抑制劑之嘧啶酮
US8445490B2 (en) 2009-10-14 2013-05-21 Bristol-Myers Squibb Company Compounds for the treatment of hepatitis C
US8586584B2 (en) 2009-10-14 2013-11-19 Bristol-Myers Squibb Company Compounds for the treatment of hepatitis C
WO2011075643A1 (fr) 2009-12-18 2011-06-23 Incyte Corporation Dérivés condensés d'hétéroaryles substitués à titre d'inhibiteurs de pi3k
WO2011130342A1 (fr) 2010-04-14 2011-10-20 Incyte Corporation Dérivés condensés en tant qu'inhibiteurs de ρi3κδ
US8741884B2 (en) 2010-05-04 2014-06-03 Bristol-Myers Squibb Company Compounds for the treatment of hepatitis C
US9062055B2 (en) 2010-06-21 2015-06-23 Incyte Corporation Fused pyrrole derivatives as PI3K inhibitors
US8765944B2 (en) 2010-08-19 2014-07-01 Bristol-Myers Squibb Company Compounds for the treatment of hepatitis C
EP3660016A1 (fr) 2010-12-20 2020-06-03 Incyte Holdings Corporation N-(1-(phényl substitué)éthyl)-9h-purin-6-amines en tant qu'inhibiteurs de pi3k
US9108984B2 (en) 2011-03-14 2015-08-18 Incyte Corporation Substituted diamino-pyrimidine and diamino-pyridine derivatives as PI3K inhibitors
WO2012135009A1 (fr) 2011-03-25 2012-10-04 Incyte Corporation Dérivés de pyrimidine-4,6-diamine en tant qu'inhibiteurs de pi3k
US8933066B2 (en) 2011-04-14 2015-01-13 Bristol-Myers Squibb Company Compounds for the treatment of hepatitis C
CN103492389B (zh) 2011-04-21 2016-09-14 原真股份有限公司 用作激酶抑制剂的吡唑并[4,3-d]嘧啶
SMT201900243T1 (it) 2011-09-02 2019-07-11 Incyte Holdings Corp Eterociclilammine come inibitori di pi3k
AP2014007475A0 (en) 2011-09-22 2014-02-28 Pfizer Pyrrolopyrimidine and purine derivates
US8629150B2 (en) 2011-09-28 2014-01-14 Bristol-Myers Squibb Company Compounds for the treatment of hepatitis C
US8697706B2 (en) 2011-10-14 2014-04-15 Bristol-Myers Squibb Company Compounds for the treatment of hepatitis C
US8916702B2 (en) 2012-02-06 2014-12-23 Bristol-Myers Squibb Company Compounds for the treatment of hepatitis C
AR090548A1 (es) 2012-04-02 2014-11-19 Incyte Corp Azaheterociclobencilaminas biciclicas como inhibidores de pi3k
CN104540830A (zh) * 2012-06-07 2015-04-22 霍夫曼-拉罗奇有限公司 端锚聚合酶的吡唑并嘧啶酮和吡唑并吡啶酮抑制剂
CN102827085A (zh) * 2012-09-17 2012-12-19 符爱清 2,4,5-三氯嘧啶化合物的制备方法
CN102952086B (zh) * 2012-09-28 2013-08-28 天津科创医药中间体技术生产力促进有限公司 一种2-吗啉基取代嘧啶类化合物的制备方法
CN102887860B (zh) * 2012-09-29 2015-07-01 上海泰坦科技有限公司 4-氯-6-三氟甲基嘧啶类化合物的制备方法
US9422311B2 (en) 2012-10-18 2016-08-23 Bristol-Myers Squibb Company Compounds for the treatment of hepatitis C
US9637491B2 (en) * 2012-10-19 2017-05-02 Origenis Gmbh Pyrazolo[4,3-D]pyrimidines as kinase inhibitors
JP5823657B1 (ja) 2012-11-08 2015-11-25 ファイザー・インク ドーパミンｄ１リガンドとしての複素芳香族化合物
CN105008360B (zh) * 2012-12-20 2017-09-19 Ucb生物制药私人有限公司 治疗活性的吡唑并嘧啶衍生物
JP2016507559A (ja) 2013-02-07 2016-03-10 ブリストル−マイヤーズ スクイブ カンパニーＢｒｉｓｔｏｌ−Ｍｙｅｒｓ Ｓｑｕｉｂｂ Ｃｏｍｐａｎｙ Ｈｃｖエントリー阻害剤としての大環状分子
CN104995197A (zh) 2013-02-07 2015-10-21 百时美施贵宝公司 作为hcv入胞抑制剂的大环化合物
CN105143233A (zh) 2013-03-07 2015-12-09 百时美施贵宝公司 用于治疗丙型肝炎的化合物
LT2964646T (lt) * 2013-03-07 2017-07-10 F. Hoffmann-La Roche Ag Nauji pirazolo dariniai
WO2014177490A1 (fr) 2013-05-02 2014-11-06 F. Hoffmann-La Roche Ag Dérivés de la purine en tant qu'agonistes du récepteur cb2
DK2991988T3 (en) 2013-05-02 2017-08-21 Hoffmann La Roche Pyrrolo [2,3-d] pyrimidine derivatives as CB2 receptor agonists
WO2015005491A1 (fr) 2013-07-12 2015-01-15 国立大学法人京都大学 Procédé de criblage d'une substance capable d'inhiber l'épissage anormal provoquant l'apparition ou l'évolution d'une maladie
EP3057592B1 (fr) * 2013-10-18 2019-05-22 Indiana University Research and Technology Corporation Effecteurs d'assemblage de virus de l'hépatite b
UA115388C2 (uk) 2013-11-21 2017-10-25 Пфайзер Інк. 2,6-заміщені пуринові похідні та їх застосування в лікуванні проліферативних захворювань
EP3104706B1 (fr) * 2014-02-11 2022-03-23 Mitokinin, Inc. Compositions et procédés les utilisant pour le traitement de maladie neurodégénérative et mitochondriale
EP3134087B1 (fr) 2014-04-25 2020-03-18 Pfizer Inc Composés hétéroaromatiques et leur utilisation en tant que ligands du récepteur d1 de la dopamine
US9868744B2 (en) 2014-04-25 2018-01-16 Pfizer Inc. Heteroaromatic compounds and their use as dopamine D1 ligands
US10077277B2 (en) 2014-06-11 2018-09-18 Incyte Corporation Bicyclic heteroarylaminoalkyl phenyl derivatives as PI3K inhibitors
BR112017015019A2 (pt) 2015-01-16 2018-01-30 The General Hospital Corporation compostos para melhorar a splicing de mrna
WO2016138363A1 (fr) 2015-02-27 2016-09-01 Incyte Corporation Sels d'un inhibiteur de pi3k et procédés de préparation de ces sels
CN107922377A (zh) 2015-04-17 2018-04-17 美国印第安纳大学研究和技术公司 乙肝病毒组装效应子
US9988401B2 (en) 2015-05-11 2018-06-05 Incyte Corporation Crystalline forms of a PI3K inhibitor
US9732097B2 (en) 2015-05-11 2017-08-15 Incyte Corporation Process for the synthesis of a phosphoinositide 3-kinase inhibitor
WO2018049214A1 (fr) 2016-09-09 2018-03-15 Incyte Corporation Dérivés de pyrazolopyridine comme modulateurs de hpk1 et leurs utilisations pour le traitement du cancer
US20180072741A1 (en) 2016-09-09 2018-03-15 Incyte Corporation Pyrazolopyrimidine compounds and uses thereof
WO2018049191A1 (fr) 2016-09-09 2018-03-15 Incyte Corporation Dérivés de pyrazolopyridone en tant que modulateurs de hpk1 et leurs utilisations pour le traitement du cancer
ES2927104T3 (es) 2016-09-09 2022-11-02 Incyte Corp Derivados de pirazolopiridina como moduladores de HPK1 y usos de los mismos para el tratamiento del cáncer
WO2018064135A1 (fr) * 2016-09-30 2018-04-05 Asana Biosciences, Llc Composés p2x3 et/ou p2x2/3 et méthodes associées
WO2018152220A1 (fr) 2017-02-15 2018-08-23 Incyte Corporation Composés de pyrazolopyridine et leurs utilisations
JP7129095B2 (ja) 2017-02-20 2022-09-01 国立大学法人京都大学 スプライシング異常に起因する遺伝性疾病のための医薬組成物及び治療方法
CA3067695A1 (fr) 2017-06-21 2018-12-27 Mitokinin, Inc. Compositions et methodes les utilisant pour le traitement d'une maladie neurodegenerative et mitochondriale
CN107383014B (zh) * 2017-06-21 2019-04-30 南方医科大学 一种1H-吡唑并[3,4-d]嘧啶类化合物及其制备方法和应用
CN109384782A (zh) 2017-08-04 2019-02-26 厦门大学 取代五元并六元杂环类化合物、其制备方法、药物组合及其用途
WO2019051199A1 (fr) 2017-09-08 2019-03-14 Incyte Corporation Composés de 6-cyano-indazole utilisés en tant que modulateurs de kinase 1 progénitrices hématopoïétiques (hpk1)
KR20200133747A (ko) 2018-02-20 2020-11-30 인사이트 코포레이션 암을 치료하기 위한 hpk1 억제제로서의 n-(페닐)-2-(페닐)피리미딘-4-카복스아미드 유도체 및 관련 화합물
US10745388B2 (en) 2018-02-20 2020-08-18 Incyte Corporation Indazole compounds and uses thereof
WO2019164847A1 (fr) 2018-02-20 2019-08-29 Incyte Corporation Composés d'indazole et leurs utilisations
US11299473B2 (en) 2018-04-13 2022-04-12 Incyte Corporation Benzimidazole and indole compounds and uses thereof
AU2019277560B2 (en) 2018-06-01 2025-04-24 Incyte Corporation Dosing regimen for the treatment of PI3K related disorders
US10899755B2 (en) 2018-08-08 2021-01-26 Incyte Corporation Benzothiazole compounds and uses thereof
MA53726A (fr) 2018-09-25 2022-05-11 Incyte Corp Composés pyrazolo[4,3-d]pyrimidine en tant que modulateurs des alk2 et/ou fgfr
US12054488B2 (en) 2018-09-27 2024-08-06 Suzhou Raymon Pharmaceuticals Company, Ltd. Pyrazolopyrimidine compound and preparation method therefor and use thereof in preparation of anti-cancer drug
CN110698432B (zh) * 2018-11-07 2023-02-03 中国医学科学院医药生物技术研究所 苯甲基哌嗪类化合物及其制备方法和在抗病毒中的应用
CN111170992B (zh) * 2018-11-12 2021-05-14 新发药业有限公司 一种5,6-二氢吡啶-2(1h)-酮衍生物的制备方法
WO2020117972A1 (fr) * 2018-12-04 2020-06-11 The Board Of Regents Of The University Of Texas System Agents thérapeutiques ciblant la polypose adénomateuse colique (apc) mutante pour le traitement du cancer
US12398140B2 (en) 2019-02-13 2025-08-26 Ptc Therapeutics, Inc. Substituted pyrrolo [2,3-d]pyrimidines for treating familial dysautonomia
US12384797B2 (en) 2019-02-13 2025-08-12 Ptc Therapeutics, Inc. Thioeno[3,2-b] pyridin-7-amine compounds for treating familial dysautonomia
EP3955929B1 (fr) * 2019-04-18 2024-05-15 Université de Liège Nouveaux dérivés de pyrimidine pour la prévention et le traitement d'infections bactériennes à gram négatif, de la contamination et de l'encrassement
CN110437253A (zh) * 2019-08-06 2019-11-12 复旦大学 含联苯结构的二芳基嘧啶并环化合物及其制备方法和用途
AU2020326703A1 (en) 2019-08-06 2022-02-17 Incyte Corporation Solid forms of an HPK1 inhibitor
CA3153096A1 (fr) 2019-09-13 2021-03-18 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Inhibiteurs du recepteur de la tyrosine kinase pour le traitement de maladie ou de trouble sensible a la modulation de la proteine kinase
EP3800188A1 (fr) 2019-10-02 2021-04-07 Bayer AG Pyrazolopyrimidines substituées en tant qu'inhibiteurs d'irak4
US11939307B2 (en) 2019-11-29 2024-03-26 Institute Of Medicinal Biotechnology, Chinese Academy Of Medical Sciences Phenylmethyl-piperazine derivatives and antiviral uses thereof
US20230121698A1 (en) * 2019-12-23 2023-04-20 Sanford Burnham Prebys Medical Discovery Institute Ectonucleotide pyrophosphatase/phosphodiesterase 1 (enpp1) modulators and uses thereof
US20230257357A1 (en) * 2020-06-29 2023-08-17 Bacainn Biotherapeutics, Ltd. Probenecid compounds for the treatment of inflammasome-mediated lung disease
CN111732575B (zh) * 2020-08-03 2020-12-11 北京鑫开元医药科技有限公司 一种n-(3-(嘧啶-2-基)苯基)苯磺酰胺类衍生物、药物组合物、制备方法及应用
WO2022123310A1 (fr) * 2020-12-11 2022-06-16 Ildong Pharmaceutical Co., Ltd. Nouveaux composés en tant qu'inhibiteurs doubles du récepteur des androgènes et de la phosphodiestérase
CN113292452B (zh) * 2021-06-01 2023-03-24 山东京博生物科技有限公司 一种氰基乙酰胺的合成方法
CN113979945A (zh) * 2021-11-15 2022-01-28 湖北理工学院 一种制备3-氨基吡唑-4-甲酰胺半硫酸盐的新方法
EP4634186A1 (fr) 2022-12-16 2025-10-22 Astrazeneca AB Purines 2,6,9-trisubstituées
WO2024168104A2 (fr) * 2023-02-09 2024-08-15 Caraway Therapeutics, Inc. Modulateurs de trpml, leurs compositions et procédés d'utilisation
WO2024168106A2 (fr) * 2023-02-09 2024-08-15 Caraway Therapeutics, Inc. Modulateurs de trpml, leurs compositions et procédés d'utilisation

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5478830A (en) * 1992-05-29 1995-12-26 The Du Pont Merck Pharmaceutical Company Fused-ring heterocycles for the treatment of atherosclerosis
JP2004506737A (ja) * 2000-08-18 2004-03-04 アグーロン　ファーマシューティカルズ，インコーポレイテッド ピラゾール化合物、薬剤組成物、およびｅｒａｂまたはｈａｄｈ２活性の調節または阻害方法
WO2005121107A1 (fr) * 2004-06-09 2005-12-22 F. Hoffmann-La Roche Ag Pyrazolopyrimidines
WO2006132460A1 (fr) * 2005-06-10 2006-12-14 Dong-A Pharmaceutical.Co., Ltd. Agent pour la prevention et le traitement des maladies du foie contenant un derive de la pyrazolopyrimidine

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5478830A (en) * 1992-05-29 1995-12-26 The Du Pont Merck Pharmaceutical Company Fused-ring heterocycles for the treatment of atherosclerosis
JP2004506737A (ja) * 2000-08-18 2004-03-04 アグーロン　ファーマシューティカルズ，インコーポレイテッド ピラゾール化合物、薬剤組成物、およびｅｒａｂまたはｈａｄｈ２活性の調節または阻害方法
WO2005121107A1 (fr) * 2004-06-09 2005-12-22 F. Hoffmann-La Roche Ag Pyrazolopyrimidines
WO2006132460A1 (fr) * 2005-06-10 2006-12-14 Dong-A Pharmaceutical.Co., Ltd. Agent pour la prevention et le traitement des maladies du foie contenant un derive de la pyrazolopyrimidine

Cited By (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9359349B2 (en) 2007-10-04 2016-06-07 Intellikine Llc Substituted quinazolines as kinase inhibitors
US8637542B2 (en) 2008-03-14 2014-01-28 Intellikine, Inc. Kinase inhibitors and methods of use
US8993580B2 (en) 2008-03-14 2015-03-31 Intellikine Llc Benzothiazole kinase inhibitors and methods of use
US9637492B2 (en) 2008-03-14 2017-05-02 Intellikine Llc Benzothiazole kinase inhibitors and methods of use
US9096611B2 (en) 2008-07-08 2015-08-04 Intellikine Llc Kinase inhibitors and methods of use
US9828378B2 (en) 2008-07-08 2017-11-28 Intellikine Llc Kinase inhibitors and methods of use
US8476282B2 (en) 2008-11-03 2013-07-02 Intellikine Llc Benzoxazole kinase inhibitors and methods of use
US8476431B2 (en) 2008-11-03 2013-07-02 Itellikine LLC Benzoxazole kinase inhibitors and methods of use
US9295673B2 (en) 2011-02-23 2016-03-29 Intellikine Llc Combination of mTOR inhibitors and P13-kinase inhibitors, and uses thereof
US9718825B2 (en) 2013-03-13 2017-08-01 Sanofi N-(4-(azaindazol-6-yl)-phenyl)-sulfonamides and their use as pharmaceuticals
US11730736B2 (en) 2017-11-06 2023-08-22 Rapt Therapeutics, Inc. Anticancer agents

Also Published As

Publication number Publication date
WO2010118367A2 (fr) 2010-10-14

Similar Documents

Publication Publication Date Title
WO2010118367A3 (fr) Pyrimidines antivirales
WO2009091388A3 (fr) Triazines et composés associés présentant une activité antivirale, compositions et procédés associés
WO2011041713A3 (fr) Agents anti-viraux à base de pipérazinyle
MX2010009563A (es) Compuestos quimicos con accion antiviral contra virus de dengue y otros flavivirus.
EP2853531A3 (fr) Composés antiviraux
PH12012502343A1 (en) Antiviral drugs for treatment or prevention of dengue infection
WO2008133753A3 (fr) Composés antiviraux
EA201390538A1 (ru) Противовирусные соединения
EA201000556A1 (ru) Спиропирролидины и их применение для борьбы с инфицированием посредством hcv (вирус гепатита с) и вич (вирус иммунодефицита человека)
WO2010081082A3 (fr) Dérivés de phosphoramidate de composés guanosine nucléoside pour le traitement d'infections virales
IL195025A (en) History of compressed indolubenzazepine with cyclopropyl and pharmaceuticals containing them as an anti-hcv drug
TN2012000264A1 (en) Hepatitis c virus inhibitors
TN2012000214A1 (en) Hepatitis c virus inhibitors
MX2011008045A (es) Inhibidores del virus de la hepatitis c.
MY152971A (en) Hepatitis c virus inhibitors
WO2012092484A3 (fr) Nucléosides puriques substitués, dérivés phosphoramidate et phosphorodiamidate pour le traitement d'infections virales
WO2008021936A3 (fr) Inhibiteurs du virus de l'hépatite c
ATE475660T1 (de) Antivirale verbindungen
WO2011106992A8 (fr) Inhibiteurs de polymérase du virus de l'hépatite c ns5b
MX2011010905A (es) Compuestos antivirales.
WO2010055164A3 (fr) Nouveaux inhibiteurs de la réplication de flavivirus
CA2862755A1 (fr) Composes antiviraux avec une fraction dibenzooxaheterocycle
WO2009094190A3 (fr) Méthodes de traitement d’infections virales
AU2012332832A8 (en) Compositions useful for the treatment of viral diseases
JO3281B1 (ar) مركبات بينزوفوران لمعالجة عدوى فيروس إلتهاب الكبد الوبائي

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 10762525

Country of ref document: EP

Kind code of ref document: A2

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 10762525

Country of ref document: EP

Kind code of ref document: A2